INTRODUCTION: Compared to subcutaneous fat, visceral fat is more metabolically active, leading to chronic inflammation and tumorigenesis. The aim of this study is to describe the effect of visceral obesity on colorectal cancer outcomes using computed tomography (CT) imaging to measure visceral fat. MATERIALS AND METHODS: We conducted a retrospective chart review of patients who underwent surgical resection for colorectal cancer. Visceral fat volume was measured by preoperative CT scans. Final analysis was performed by stratifying patients based on oncologic stage. RESULTS: Two hundred nineteen patients met the inclusion criteria, 111 viscerally obese and 108 nonobese. Body mass index (BMI) weakly correlated with visceral fat volume measurements (R (2) = 0.304). Whereas obese patients had no difference in survival when categorizing obesity by BMI, categorizing based on visceral fat volume resulted in significant differences in stage II and stage III patients. In stage II cancer, viscerally obese patients had a nearly threefold decrease in disease-free survival (hazard ratio (HR) = 2.72; 95 % confidence interval (CI) = 1.21, 6.10). In stage III cancer, viscerally obese patients had a longer time to recurrence (HR = 0.39; 95 % CI = 0.16, 0.99). CONCLUSION: This study shows that viscerally obese patients with stage II colorectal cancer are at higher risk for poor outcomes and should be increasingly considered for adjuvant chemotherapy.
INTRODUCTION: Compared to subcutaneous fat, visceral fat is more metabolically active, leading to chronic inflammation and tumorigenesis. The aim of this study is to describe the effect of visceral obesity on colorectal cancer outcomes using computed tomography (CT) imaging to measure visceral fat. MATERIALS AND METHODS: We conducted a retrospective chart review of patients who underwent surgical resection for colorectal cancer. Visceral fat volume was measured by preoperative CT scans. Final analysis was performed by stratifying patients based on oncologic stage. RESULTS: Two hundred nineteen patients met the inclusion criteria, 111 viscerally obese and 108 nonobese. Body mass index (BMI) weakly correlated with visceral fat volume measurements (R (2) = 0.304). Whereas obesepatients had no difference in survival when categorizing obesity by BMI, categorizing based on visceral fat volume resulted in significant differences in stage II and stage III patients. In stage II cancer, viscerally obesepatients had a nearly threefold decrease in disease-free survival (hazard ratio (HR) = 2.72; 95 % confidence interval (CI) = 1.21, 6.10). In stage III cancer, viscerally obesepatients had a longer time to recurrence (HR = 0.39; 95 % CI = 0.16, 0.99). CONCLUSION: This study shows that viscerally obesepatients with stage II colorectal cancer are at higher risk for poor outcomes and should be increasingly considered for adjuvant chemotherapy.
Authors: Nikiforos Ballian; Meghan G Lubner; Alejandro Munoz; Bruce A Harms; Charles P Heise; Eugene F Foley; Gregory D Kennedy Journal: J Surg Oncol Date: 2011-07-12 Impact factor: 3.454
Authors: Luis Gruberg; Neil J Weissman; Ron Waksman; Shmuel Fuchs; Regina Deible; Ellen E Pinnow; Lanja M Ahmed; Kenneth M Kent; Augusto D Pichard; William O Suddath; Lowell F Satler; Joseph Lindsay Journal: J Am Coll Cardiol Date: 2002-02-20 Impact factor: 24.094
Authors: Anna E Prizment; Andrew Flood; Kristin E Anderson; Aaron R Folsom Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09 Impact factor: 4.254
Authors: Jeffrey A Meyerhardt; Joel E Tepper; Donna Niedzwiecki; Donna R Hollis; A David McCollum; Denise Brady; Michael J O'Connell; Robert J Mayer; Bernard Cummings; Christopher Willett; John S Macdonald; Al B Benson; Charles S Fuchs Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: Gertraud Maskarinec; Brook E Harmon; Melissa A Little; Nicholas J Ollberding; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Lynne R Wilkens Journal: Cancer Causes Control Date: 2015-09-10 Impact factor: 2.506
Authors: Chun Seng Lee; David J Murphy; Colm McMahon; Blathnaid Nolan; Garret Cullen; Hugh Mulcahy; Kieran Sheahan; Elizabeth Barnes; David Fennelly; Elizabeth J Ryan; Glen A Doherty Journal: J Gastrointest Cancer Date: 2015-09
Authors: Kathryn A Schlosser; Sean R Maloney; Tanushree Prasad; Paul D Colavita; Vedra A Augenstein; B Todd Heniford Journal: Surg Endosc Date: 2019-06-24 Impact factor: 4.584
Authors: Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-05-15 Impact factor: 4.254
Authors: Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2016-03-10 Impact factor: 2.226